(Q33579584)

28 July 2017

title

Forecasting drug utilization and expenditure in a metropolitan health region (English)

1 reference

28 July 2017

Paul Hjemdahl

6

0 references

Lars L. Gustafsson

object named as

Lars L Gustafsson

9

0 references

Max Petzold

8

object named as

Max Petzold

1 reference

28 July 2017

1

Björn Wettermark

1 reference

28 July 2017

Eva Andersén Karlsson

1 reference

ORCID Public Data File 2021

Brian Godman

7

object named as

Brian Godman

1 reference

28 July 2017

3

Nils Wilking

1 reference

28 July 2017

4

Mats Kalin

1 reference

28 July 2017

5

Seher Korkmaz

1 reference

28 July 2017

Marie E Persson

2

1 reference

28 July 2017

Regional Drug Expert Consortium in Stockholm County Council

10

1 reference

28 July 2017

publication date

17 May 2010

1 reference

BMC Health Services Research

28 July 2017

published in

1 reference

28 July 2017

volume

10

1 reference

28 July 2017

page(s)

128

1 reference

Creative Commons Attribution 2.0 Generic

28 July 2017

copyright license

start time

17 May 2010

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

1 reference

April 2022 Public Data File from Crossref

cites work

Health spending projections through 2019: the recession's impact continues

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2893175

Initial effects of a reimbursement restriction to improve the cost-effectiveness of antihypertensive treatment

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2893175

Economic consequences to society of pandemic H1N1 influenza 2009 - preliminary results for Sweden.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2893175

Ticagrelor versus clopidogrel in patients with acute coronary syndromes

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2893175

Dabigatran versus warfarin in patients with atrial fibrillation

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2893175

Dronedarone for atrial fibrillation--an odyssey

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2893175

Multifaceted national and regional drug reforms and initiatives in ambulatory care in Sweden: global relevance

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2893175

Pneumococcal conjugate vaccines for preventing otitis media

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2893175

The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2893175

Effect of dronedarone on cardiovascular events in atrial fibrillation

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2893175

Projecting future drug expenditures--2009.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2893175

Targeted drugs in chronic myeloid leukemia.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2893175

HIV epidemiology and the effects of antiviral therapy on long-term consequences.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2893175

Clinical and preclinical rationale for CGRP-receptor antagonists in the treatment of migraine

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2893175

New drugs in multiple myeloma

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2893175

Have newer cardiovascular drugs reduced hospitalization? Evidence from longitudinal country-level data on 20 OECD countries, 1995-2003.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2893175

Human papillomavirus vaccine: recommendations, issues and controversies

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2893175

Current and future management of chronic hepatitis C infection

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2893175

Review article: current management of metastatic colorectal cancer - the evolving impact of targeted drug therapies.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2893175

Dapoxetine, a novel selective serotonin transport inhibitor for the treatment of premature ejaculation

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2893175

New drugs for chronic hepatitis B: a review

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2893175

Projecting future drug expenditures--2008.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2893175

Adjuvant chemotherapy in oestrogen-receptor-poor breast cancer: patient-level meta-analysis of randomised trials

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2893175

New oral anticoagulants in atrial fibrillation

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2893175

The challenge of biosimilars

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2893175

Guidance for the treatment of neovascular age-related macular degeneration

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2893175

Pharmaceutical policies: effects of financial incentives for prescribers

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2893175

Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2893175

Effective early warning systems for new and emerging health technologies: developing an evaluation framework and an assessment of current systems.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2893175

Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2893175

Personalized medicine: elusive dream or imminent reality?

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2893175

The demise of the blockbuster?

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2893175

Cost of cancer care: issues and implications

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2893175

Use of antiepileptic drugs for nonepileptic conditions: psychiatric disorders and chronic pain

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2893175

Narrative review: lack of evidence for recommended low-density lipoprotein treatment targets: a solvable problem

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2893175

Oral anticoagulants in development: focus on thromboprophylaxis in patients undergoing orthopaedic surgery

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2893175

The new Swedish Prescribed Drug Register--opportunities for pharmacoepidemiological research and experience from the first six months

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2893175

Swedish registers to examine drug safety and clinical issues in RA.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2893175

The Patents-Based Pharmaceutical Development Process

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2893175

Emerging biologic drugs for the treatment of rheumatoid arthritis

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2893175

Emerging drug targets for antiretroviral therapy

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2893175

A pharmacogeneticist's look at drug effects and the drug development process: an overview

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2893175

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2893175

The impact of new drug launches on longevity: evidence from longitudinal, disease-level data from 52 countries, 1982-2001.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2893175

Assessing the accuracy of forecasting: applying standard diagnostic assessment tools to a health technology early warning system.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2893175

Moving towards individualized medicine with pharmacogenomics

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2893175

What drives change? Barriers to and incentives for achieving evidence-based practice

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2893175

Evidence b(i)ased medicine--selective reporting from studies sponsored by pharmaceutical industry: review of studies in new drug applications

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2893175

Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2893175

Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II)

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2893175

Drug discovery: a historical perspective

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2893175

21 June 2018

2008 FDA drug approvals.

1 reference

https://api.crossref.org/works/10.1186%2F1472-6963-10-128

Orphan drug development is not taking off.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1472-6963-10-128

European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1472-6963-10-128

International diffusion of new health technologies: a ten-country analysis of six health technologies

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1472-6963-10-128

Viagra: a success story for rationing?

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1472-6963-10-128

The global market for ADHD medications.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1472-6963-10-128

Enhancing the rational use of new medicines across European health care systems

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1472-6963-10-128

Financial incentives linked to self-assessment of prescribing patterns: a new approach for quality improvement of drug prescribing in primary care.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2893175

[A model for structured introduction of new drugs. The aim is to offer all patients appropriate treatment]

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2893175

Prescribing Incentive Schemes

31 October 2018

1 reference

https://api.crossref.org/works/10.1186%2F1472-6963-10-128

21 January 2018

When the party's over

1 reference

https://api.crossref.org/works/10.1186%2F1472-6963-10-128

Impact of a generic substitution reform on patients' and society's expenditure for pharmaceuticals

21 January 2018

1 reference

12 December 2020

Being NICE is not the problem!

1 reference

12 December 2020

Prices and distribution margins of in-patent drugs in pharmacy: a comparison in seven European countries

1 reference

12 December 2020

Ten years of rituximab in NHL

1 reference

12 December 2020

National health spending in 2006: a year of change for prescription drugs

1 reference

12 December 2020

Three new drugs for type 2 diabetes

1 reference

12 December 2020

Tier 4 drugs and the fraying of the social compact

1 reference

12 December 2020

Insulin glargine use and short-term incidence of malignancies—a population-based follow-up study in Sweden

1 reference

12 December 2020

European Commission takes on Big Pharma

1 reference

12 December 2020

Identifiers

DOI

10.1186/1472-6963-10-128

1 reference

Dimensions Publication ID

28 July 2017

0 references

1 reference

28 July 2017

1 reference